[Levels of neuropeptide Y and thromboxane B2 in patients with variant angina]

What Was Tested

The paper reports a study of Neuropeptide Y, published as a controlled clinical trial.

The aim of this study was a verification of the participation of neuropeptide Y and thromboxane B2 in etiopathogenesis of the coronary artery spasm in patients with variant angina.

Why It Was Studied

One of the causes of coronary artery spasm in patients with variant angina could be a disturbed interaction between the vasodilating action of endothelial derived relaxing factor and the vasospastic action of neuropeptide Y and thromboxane B2.

The survey was made in 38 patients with variant angina and in 18 patients with chronic stable angina pectoris.

Who Took Part

According to the abstract, 38 patients were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

What Was Measured

Before the hyperventilation test, during which the person under test has been breathing with a frequency of 40/minute through 5 minutes, the Tris (tromethamol) of pH = 10.5 has been given in intravenous infusion lasting for 5 minutes.

The neuropeptide Y and thromboxane B2 plasma levels have been determined just before the hyperventilation test, just after the termination of the test and 10 minutes after the termination of the test.

Topics PubMed links to this paper include Angina Pectoris, Angina Pectoris, Variant, Chronic Disease, Neuropeptide Y and Thromboxane B2.

What This Means in Plain Language

This is a controlled clinical trial of Neuropeptide Y in 38 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1998 (Polskie Archiwum Medycyny Wewnetrznej), a journal based in Poland.

More context: the Neuropeptide Y compound page, all human trials.